Terms: = Pancreatic cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Treatment
665 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. A pancreatic cancer organoid-in-matrix platform shows distinct sensitivities to T cell killing.
Lahusen A; Cai J; Schirmbeck R; Wellstein A; Kleger A; Seufferlein T; Eiseler T; Lin YN
Sci Rep; 2024 Apr; 14(1):9377. PubMed ID: 38654067
[TBL] [Abstract] [Full Text] [Related]
3. PELI1: key players in the oncogenic characteristics of pancreatic cancer.
Fei X; Zhu C; Liu P; Liu S; Ren L; Lu R; Hou J; Gao Y; Wang X; Pan Y
J Exp Clin Cancer Res; 2024 Mar; 43(1):91. PubMed ID: 38528516
[TBL] [Abstract] [Full Text] [Related]
4. Enhanced Anti-tumor Effect of Flavopiridol in Combination With Gemcitabine in pancreatic cancer.
Chung KH; Cho IR; Paik WH; Kim YT; Lee SH; Ryu JK
Anticancer Res; 2024 Mar; 44(3):1097-1108. PubMed ID: 38423644
[TBL] [Abstract] [Full Text] [Related]
5. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers.
Alruwaili MM; Zonneville J; Naranjo MN; Serio H; Melendy T; Straubinger RM; Gillard B; Foster BA; Rajan P; Attwood K; Chatley S; Iyer R; Fountzilas C; Bakin AV
Cell Rep Med; 2024 Mar; 5(3):101434. PubMed ID: 38387463
[TBL] [Abstract] [Full Text] [Related]
6. Integrated Multiomics Reveals Silencing of has_circ_0006646 Promotes TRIM21-Mediated NCL Ubiquitination to Inhibit Hepatocellular Carcinoma Metastasis.
Hu X; Chen G; Huang Y; Cheng Q; Zhuo J; Su R; He C; Wu Y; Liu Z; Yang B; Wang S; Meng L; Zheng S; Lu D; Wei Q; Yang J; Wei X; Chen R; Xu X
Adv Sci (Weinh); 2024 Apr; 11(16):e2306915. PubMed ID: 38357830
[TBL] [Abstract] [Full Text] [Related]
7. Transformation of G1-G2 neuroendocrine tumors to neuroendocrine carcinomas following peptide receptor radionuclide therapy.
Cordero-Hernandez IS; Ross AC; Dasari A; Halperin DM; Chasen B; Yao JC
Endocr Relat Cancer; 2024 Apr; 31(4):. PubMed ID: 38329269
[TBL] [Abstract] [Full Text] [Related]
8. A comprehensive meta-analysis of transcriptome data to identify signature genes associated with pancreatic ductal adenocarcinoma.
Kordshouli SO; Tahmasebi A; Moghadam A; Ramezani A; Niazi A
PLoS One; 2024; 19(2):e0289561. PubMed ID: 38324544
[TBL] [Abstract] [Full Text] [Related]
9. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus.
Hashimoto M; Kuroda S; Kanaya N; Kadowaki D; Yoshida Y; Sakamoto M; Hamada Y; Sugimoto R; Yagi C; Ohtani T; Kumon K; Kakiuchi Y; Yasui K; Kikuchi S; Yoshida R; Tazawa H; Kagawa S; Yagi T; Urata Y; Fujiwara T
Br J Cancer; 2024 Apr; 130(7):1187-1195. PubMed ID: 38316993
[TBL] [Abstract] [Full Text] [Related]
10. A novel method for detection of pancreatic Ductal Adenocarcinoma using explainable machine learning.
Aslam M; Rajbdad F; Azmat S; Li Z; Boudreaux JP; Thiagarajan R; Yao S; Xu J
Comput Methods Programs Biomed; 2024 Mar; 245():108019. PubMed ID: 38237450
[TBL] [Abstract] [Full Text] [Related]
11. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.
Vogel A; Haupts A; Kloth M; Roth W; Hartmann N
Diagn Pathol; 2024 Jan; 19(1):9. PubMed ID: 38184614
[TBL] [Abstract] [Full Text] [Related]
12. Nicotine promotes epithelial to mesenchymal transition and gemcitabine resistance via hENT1/RRM1 signalling in pancreatic cancer and chemosensitizing effects of Embelin-a naturally occurring benzoquinone.
Prashanth N ; Meghana P ; Sandeep Kumar Jain R ; Pooja S Rajaput ; Satyanarayan N D ; Raja Naika H ; Kumaraswamy H M
Sci Total Environ; 2024 Mar; 914():169727. PubMed ID: 38163613
[TBL] [Abstract] [Full Text] [Related]
13. cancer-Associated Fibroblast Induces Acinar-to-Ductal Cell Transdifferentiation and pancreatic cancer Initiation Via LAMA5/ITGA4 Axis.
Parte S; Kaur AB; Nimmakayala RK; Ogunleye AO; Chirravuri R; Vengoji R; Leon F; Nallasamy P; Rauth S; Alsafwani ZW; Lele S; Cox JL; Bhat I; Singh S; Batra SK; Ponnusamy MP
Gastroenterology; 2024 May; 166(5):842-858.e5. PubMed ID: 38154529
[TBL] [Abstract] [Full Text] [Related]
14. Therapeutic potential of SHCBP1 inhibitor AZD5582 in pancreatic cancer treatment.
Ma Z; Gu Q; Dai Y; Wang Q; Shi W; Jiao Z
Cancer Sci; 2024 Mar; 115(3):820-835. PubMed ID: 38151993
[TBL] [Abstract] [Full Text] [Related]
15. Precision medicine for KRAS wild-type pancreatic adenocarcinomas.
Ben-Ammar I; Rousseau A; Nicolle R; Tarabay A; Boige V; Valery M; Pudlarz T; Malka D; Gelli M; Fernandez-De-Sevilla E; Fuerea A; Tanguy ML; Rouleau E; Barbe R; Mathieu JRR; Jaulin F; Smolenschi C; Hollebecque A; Ducreux M; Boileve A
Eur J Cancer; 2024 Jan; 197():113497. PubMed ID: 38134480
[TBL] [Abstract] [Full Text] [Related]
16. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.
Uddin MH; Al-Hallak MN; Khan HY; Aboukameel A; Li Y; Bannoura SF; Dyson G; Kim S; Mzannar Y; Azar I; Odisho T; Mohamed A; Landesman Y; Kim S; Beydoun R; Mohammad RM; Philip PA; Shields AF; Azmi AS
Clin Transl Med; 2023 Dec; 13(12):e1513. PubMed ID: 38131168
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
[TBL] [Abstract] [Full Text] [Related]
18. Cost-Effectiveness Analysis of Screening for pancreatic cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract] [Full Text] [Related]
19. The genomic and immune landscapes of gastric cancer and their correlations with HER2 amplification and PD-L1 expression.
Jing X; Luo Z; Wu J; Ye F; Li J; Song Z; Zhang Y; Shi M; Sun H; Fang Y; Jiang Y; Ji X
Cancer Med; 2023 Dec; 12(24):21905-21919. PubMed ID: 38050871
[TBL] [Abstract] [Full Text] [Related]
20. tp53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma.
Zhou Y; Jin J; Ji Y; Zhang J; Fu N; Chen M; Wang J; Qin K; Jiang Y; Cheng D; Deng X; Shen B
J Transl Med; 2023 Dec; 21(1):872. PubMed ID: 38037073
[TBL] [Abstract] [Full Text] [Related]
[Next]
